Saturday 17 October 2026
Export PMVP’s income statement to Excel — free account
PMV Pharmaceuticals, Inc.
PMVP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.1% and free cash flow grew 20.3%, each against the same quarter a year earlier.
1.21
0.08
−6.20%
Follow PMVP
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 26.75 | 22.57 | 56.91 | 24.66 | 22.80 | 14.78 | 12.22 | 10.09 |
Net Debt/EBITDA |
— | 3.40 | 3.88 | 10.48 | 5.19 | 3.13 | 2.42 | 1.89 | 1.27 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.87 | 0.87 | 0.95 | 0.81 | 0.87 | 0.81 | 0.87 | 0.95 |
Capex/Depreciation |
— | (0.69) | (0.24) | (0.31) | (1.57) | 25.51 | 0.23 | 0.10 | 0.00 |
| — | 30.08% | 43.48% | (23.86%) | (17.33%) | (26.44%) | (29.24%) | (29.23%) | (55.37%) | |
| — | 0.00% | (49.21%) | (14.70%) | (16.60%) | (24.36%) | (26.40%) | (26.48%) | (50.51%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (344.55%) | (1,159.68%) | (229.63%) | (805.99%) | 0.00% |
Return on Tangible Assets |
— | (28.78%) | (25.79%) | (9.60%) | (19.80%) | (29.67%) | (33.80%) | (36.31%) | (74.72%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (5.19) | (7.31) | (2.29) | (1.06) | (1.57) | (1.18) | (1.00) | (1.40) |
Cash per Share |
— | 20.55 | 33.44 | 25.16 | 6.60 | 5.30 | 4.25 | 3.29 | 2.15 |
Shareholders Equity per Share |
— | 0.00 | (23.22) | 25.00 | 6.84 | 5.40 | 4.70 | 3.41 | 1.99 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | (23.22) | 25.00 | 6.84 | 5.40 | 4.70 | 3.41 | 1.99 |
Free Cash Flow |
— | (15.63) | (22.17) | (32.89) | (47.92) | (71.74) | (56.62) | (51.69) | (73.57) |
Working Capital |
— | 59.91 | 97.57 | 358.35 | 289.07 | 236.17 | 193.38 | 161.29 | 103.81 |
Capital Expenditures |
— | (0.45) | (0.11) | (0.15) | (1.35) | (7.98) | (0.96) | (0.40) | 0.00 |
Net Current Asset Value |
— | 62.24 | (71.41) | 358.35 | 278.28 | 222.73 | 180.95 | 160.45 | 103.38 |
| Other line items | |||||||||
Quick Ratio |
— | 26.60 | 22.44 | 56.38 | 24.39 | 22.33 | 14.53 | 11.79 | 9.89 |
Depreciation/Fixed assets |
— | 0.65 | 0.61 | 0.83 | 0.28 | (0.03) | (0.39) | (10.33) | (11.13) |
Cash ROIC |
— | (25.25%) | (71.50%) | (4.56%) | (7.90%) | (14.70%) | (13.18%) | (14.96%) | (33.80%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (5.04) | (7.27) | (2.28) | (1.03) | (1.40) | (1.16) | (0.99) | (1.40) |
Capex per Share |
— | (0.15) | (0.04) | (0.01) | (0.03) | (0.18) | (0.02) | (0.01) | 0.00 |
Average Payables |
— | 1.94 | 1.94 | 2.22 | 2.40 | 3.09 | 3.12 | 4.91 | 4.87 |
Average Assets |
— | 0.00 | 51.52 | 234.28 | 348.55 | 300.94 | 261.23 | 221.72 | 153.93 |
Average Common Equity |
— | (58.31) | (58.31) | 144.32 | 333.84 | 277.29 | 235.86 | 200.88 | 140.40 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates